Beta Bionics Investors Face Nov. 3 Lead Plaintiff Deadline
Investors in Beta Bionics have until November 3, 2026, to seek the lead plaintiff role in a securities fraud class action.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Beta Bionics faces securities class action
Beta Bionics faces a securities class action over claims tied to its iLet automated insulin delivery system and alleged failures around FDA concerns. The case seeks to represent investors who bought the stock between July 30, 2025 and Feb. 24, 2026.
Beta Bionics faces securities fraud class action
Beta Bionics faces a securities class action tied to allegations over disclosures about its iLet automated insulin delivery system and FDA concerns. The suit seeks to represent investors who bought shares between July 30, 2025 and Feb. 24, 2026.